News

/News
News2021-02-25T18:54:39+01:00

Last news

911, 2022

Customers in selected countries now purchase Cytognos references directly from BD

November 9th, 2022|News|

Customers in selected countries now purchase Cytognos references directly from BD As of November 9, 2022, customers in the following countries will purchase Cytognos products directly through BD: Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, Switzerland, the Netherlands and the UK. You can check your current supplier here.

102, 2022

BD Expands Flow Cytometry Portfolio with Acquisition of Cytognos

February 1st, 2022|News|

BD Expands Flow Cytometry Portfolio with Acquisition of Cytognos As the understanding and treatment of cancer evolves and improves, the importance of monitoring post-remission cancer survivors has become paramount to improving patient outcomes. Monitoring for minimal residual disease, or MRD, lab managers and physicians can detect low levels of cancer cells following treatment that can signal cancer recurrence. This is a key element of the patient care continuum that [...]

1105, 2021

Cytognos would like to announce the Infinicyt™ CE-IVD Edition

May 11th, 2021|News|

Cytognos would like to announce the Infinicyt™ CE-IVD Edition Infinicyt™ is a well established software in the field of clinical flow cytometry. It is recognized for being an agile software that incorporates state-of-the-art technology with the aim of facilitating multi-parametric analyses, that are becoming more and more complete and complex. With the release of Infinicyt™ 2.0.5, the RUO and the CE-IVD version under the European Directive 98/79/EC (IVDD) will [...]

103, 2021

The Josep Carreras Leukemia Research Institute and Cytognos S.L. develop a kit for the prognosis of Acute Myeloid Leukemia

March 1st, 2021|News|

The Josep Carreras Research Institute and Cytognos S.L. develop a kit to determine the prognosis of patients diagnosed with Acute Myeloid Leukaemia The Joint Cytometry Unit, formed by the Josep Carreras Leukemia Research Institute and the company Cytognos S.L., has developed a new commercial reagent that helps determine the prognosis of patients with Acute Myeloid Leukemia at the time of diagnosis. Acute Myeloid Leukemia (AML) is a very aggressive [...]

Cytognos™, Infinicyt™, APC-750™, OC515™, Bulklysis™ and Next Generation Flow™ are trademarks or registered trademarks of Cytognos, S.L.
EuroFlow™ is a trademark or registered trademark of The European Scientific foundation for Laboratory Hemato Oncology (ESLHO).
BD FACSCanto™ II and BD FACSLyric™ are trademarks or registered trademarks of Becton, Dickinson and Company or its affiliates.

All products listed are labeled with some regulatory status as per indicated below:
RUO” or “For Research Use Only”: for Research Use Only. Not for use in diagnostic or therapeutic procedures.
CE-IVD”: in vitro diagnostic medical device bearing a CE mark.
LUO” or “Laboratory Use Only”: general purpose laboratory reagents.
ASR” or “Analyte Specific Reagent”: reagents in which the analytical and performance characteristics are not established. ASRs are regulated by the US Food and Drug Administration (FDA).

preloader